Cancer treatment in India is about to get a little less punishing on the family budget. The government has said that prices of 120 anti-cancer medicines will fall sharply from November 9, with the steepest cut reaching 96.45 per cent, and patients could together save an estimated Rs 3,357.49 crore.
The announcement, made through an official factsheet on Friday, November 6, comes a day before National Cancer Awareness Day. For families that have watched medicine bills pile up month after month, the timing could hardly be better.
What changed, and why prices are falling
The National Pharmaceutical Pricing Authority, or NPPA, capped the trade margin on 137 non-scheduled anti-cancer medicines at 30 per cent of the maximum retail price on October 17. The cap covers patented drugs too, and it targets the mark-ups that build up along the supply chain, in distribution, retail shops and hospital pharmacies.
Since the order, 70 companies have submitted revised maximum retail prices for 120 of those medicines. The cuts average between 20 per cent and 70 per cent, and the revised prices take effect from November 9. A medicine already priced below the new limit cannot be made more expensive.
The NPPA has put the revised prices on its website, and the list is updated as companies submit figures.
Some medicines now cost a fraction of their old price
The numbers behind the announcement are striking. Palbociclib, sold as Palbopro and used to treat certain types of breast cancer, has seen the price of a pack of 21 capsules fall from Rs 40,421 to Rs 2,720, a drop of about 93 per cent. Abiraterone, sold as Abiralive and used in prostate cancer treatment, is now cheaper by about 83 per cent, falling from Rs 28,000 to Rs 4,840.
The biggest reduction in rupee terms is for thiotepa, a chemotherapy drug. One 100 mg vial has dropped from Rs 80,071.86 to Rs 7,150.33, a saving of Rs 72,921.53 on a single vial. In all, the NPPA has revised maximum retail prices for 543 formulations across the 137 cancer drugs covered by the order.
- Palbociclib (Palbopro), 21 capsules: Rs 40,421 down to Rs 2,720, about 93 per cent cheaper
- Abiraterone (Abiralive): Rs 28,000 down to Rs 4,840, about 83 per cent cheaper
- Thiotepa, 100 mg vial: Rs 80,071.86 down to Rs 7,150.33, a cut of Rs 72,921.53
- Steepest single reduction across all revised drugs: 96.45 per cent
How the Rs 3,357 crore figure was worked out
The estimated savings of Rs 3,357.49 crore is the difference between the old and revised prices, applied to the volume of these medicines sold between April 2025 and March 2026. It is a projection based on past sales, not money that patients have already saved. The NPPA has separately estimated that annual spending on cancer care could fall by Rs 2,500 crore to Rs 3,500 crore once the new prices are in force.
The new prices have been worked out from the distributor price of March 2026, which gives patients a fixed reference point to check against.
Why this matters for Indian families
Cancer remains one of the heaviest financial burdens a family can face in India. According to International Agency for Research on Cancer estimates, India recorded about 14.13 lakh new cancer cases in 2022. For many patients, the cost of medicines continues long after the hospital stay ends, and it is often paid out of pocket.
That is why a price cut on medicines, rather than only on hospital charges, reaches so many people. A patient who needs the same drug every month will feel the difference in every bill, not just once. The cap also reaches hospital pharmacies, where mark-ups have often been the highest.
What patients should keep in mind
The relief is real, but it is not uniform. Several top-selling patented drugs have not seen price cuts, so the actual benefit will depend on the specific medicine and brand a doctor prescribes. Patients should check the revised price of their own medicine on the NPPA website or the Pharma Sahi Daam app before their next purchase.
It is also worth remembering that the cap addresses medicine prices, not the full cost of cancer care. Hospital stays, tests, radiation and surgery sit outside this order. Even so, for a disease where treatment can stretch over months and years, cheaper medicines remove one of the heaviest recurring costs.
FAQs
When do the new cancer drug prices take effect?
The revised prices take effect from November 9, 2026.
How many cancer medicines have become cheaper?
Price revisions have been made for 120 of the 137 non-scheduled anti-cancer medicines covered by the NPPA order, across 543 formulations.
How much can patients save in total?
The government estimates savings of Rs 3,357.49 crore, worked out from the volume of medicines sold between April 2025 and March 2026.
Which medicine saw the biggest price cut?
The steepest single reduction is 96.45 per cent. In rupee terms, thiotepa saw the largest cut, falling by Rs 72,921.53 per vial.
Where can patients check the new prices?
On the NPPA website and on the official Pharma Sahi Daam mobile app.
For families dealing with cancer, every rupee saved on medicines is a rupee that can go towards the rest of the fight. From November 9, patients should start seeing the difference on their bills.
